A recent paper filed with the Securities and Exchange Commission (SEC) showed that ReCor Medical, a developer of renal neurosurgery equipment, has completed a new round of debt financing of $10 million. It is well known that the kidney is an important organ that regulates the balance of water, electrolytes and acid-base. It also regulates circulating volume and vascular tone by secreting renin, prostaglandins, kinins and other substances, thus playing an important role in maintaining and regulating blood pressure. . Renal denervation has become a new way to treat refractory hypertension, as seen in earlier reports. ReCor Medical, which has offices in California and Amsterdam, the Netherlands, says it has developed a unique unfocused ultrasound treatment system for kidney denervation. The system, called Paradise, uses a small flexible catheter that is inserted into the incision near the groin to deliver ultrasound energy to the surrounding tissue, ablated to the nerve endings on the inner wall of the renal artery, thereby reducing renal nerve activity. According to the US Securities and Exchange Commission, the current round of funding comes from an anonymous investor. However, the company has not disclosed how this round of financing will be spent. In May of this year, ReCor announced that it has received a strategic investment from Otsuka Pharmaceutical (Tokyo: 40878), which will allow ReCor to enter the Asian market. Although neither party disclosed financial terms, the transaction required Otsuka Pharmaceutical to obtain exclusive rights to apply for clinical trials, regulatory approvals, and commercialization in Japan, Japan, South Korea and other Asian countries. Otsuka Pharmaceutical will first test in Japan whether Paradise can help patients with refractory hypertension. It is understood, ReCor was in April 2015 gained the lead investor Otsuka Pharmaceutical $ 15 million Series D investment, the company plans to use the money to fund its IDE (the investigational device exemption, the exemption of medical devices for the US trial The systemic approved radiation hypertension study will examine the effects of the Paradise system on hypertensive patients in the United States and the European Union. In February 2016, ReCor approved the IDE and announced in April the first study of 292 patient studies. Dietary supplements take vitamins, minerals and extracts with relatively clear structure-activity relationship as the main raw materials, and supplement the necessary nutrients and biologically active substances for the human body through oral intake to achieve the purpose of improving the body's health and reducing the risk of disease. Available in concentrated forms such as doses or capsules. Foods in traditional form with added nutrients or biologically active substances. Dietary supplement,New Dietary Ingredient,Dietary Supplement Product,Food Supplements YT(Xi'an) Biochem Co., Ltd. , https://www.ytherblifes.com
Kidney denervation equipment developer ReCor Medical completes $10 million in debt financing